Yes, add an MRA immediately—it is a foundational pillar of HFrEF therapy with Class I recommendation
An MRA should absolutely be added to the regimen of any adult with HFrEF (EF ≤35%) already on ACE-I/ARB/ARNI, beta-blocker, and SGLT2 inhibitor. MRAs are not optional add-ons but rather one of the four foundational pillars of guideline-directed medical therapy (GDMT) for HFrEF, carrying the same Class I, Level A recommendation as the other neurohormonal antagonists 1.
Why MRAs Are Essential
The 2022 ACC/AHA/HFSA guidelines explicitly position MRAs as part of the initial horizontal treatment algorithm for HFrEF, alongside ACE-I/ARB/ARNI, beta-blockers, and SGLT2 inhibitors 1. This represents a shift from sequential therapy to simultaneous initiation of all four drug classes. The evidence base is unequivocal:
- Mortality and morbidity reduction: MRAs provide significant reductions in cardiovascular death, sudden cardiac death, and heart failure hospitalizations 2
- Early benefit: Aldosterone blockade exerts rapid clinical benefits, often within days of initiation, and prevents irreversible adverse ventricular remodeling 2
- Synergistic effects: The combination of ARNI/ACE-I + beta-blocker + MRA + SGLT2i demonstrates superior outcomes compared to incomplete regimens 3, 4
The Cost of Omission
Delaying or omitting MRA therapy—even by weeks—is associated with increased mortality, recurrent hospitalizations, and irreversible cardiac damage 2. Real-world data from 315,342 German patients showed that four-drug therapy (including MRA) reduced mortality risk by 8% (adjusted HR 0.92,95% CI 0.86-0.97) compared to two-drug therapy, with one-year survival of 88.2% versus 83.1% 4. The four-drug regimen also reduced all-cause readmissions (HR 0.76) and HF-specific readmissions (HR 0.90) 4.
Practical Implementation
Initiation Strategy
- Start MRA early—ideally as part of the "four drugs in 4 weeks" approach 5
- Begin with spironolactone 12.5-25 mg daily or eplerenone 25 mg daily
- Do not wait for target doses of other medications before adding MRA 1
Monitoring and Titration
- Check potassium and creatinine within 1 week of initiation, then at 4 weeks, then periodically
- Target dose: spironolactone 25-50 mg daily or eplerenone 50 mg daily
- Acceptable potassium range: <5.5 mEq/L
Overcoming Hyperkalemia Barriers
Hyperkalemia concerns should not prevent MRA use. A structured approach enables safe optimization even in high-risk patients 6:
- Dietary potassium restriction via dietitian consultation
- Remote monitoring of electrolytes
- Potassium binders (patiromer, sodium zirconium cyclosilicate) when needed—these enable MRA continuation in 53% of high-risk patients 6
- Interdisciplinary care significantly improves MRA optimization rates (HR 4.67,95% CI 1.93-11.27) 6
Common Pitfalls to Avoid
- Waiting for "stability": MRAs should be initiated early, not delayed until other medications are optimized
- Excessive caution with potassium: Potassium 5.0-5.5 mEq/L is manageable with dietary modification and binders—do not reflexively discontinue
- Underutilization: Despite Class I recommendations, MRAs remain prescribed in only 35.6% of eligible patients in real-world practice 4—this represents a major treatment gap
- Ignoring SGLT2i synergy: SGLT2 inhibitors reduce hyperkalemia risk when combined with MRAs, making the combination safer than MRA monotherapy 7
Evidence Hierarchy
The guideline recommendation 1 is reinforced by meta-analytic data showing that ARNI + BB + MRA + SGLT2i improves LVEF by 15.63% compared to placebo, and is superior to the traditional "golden triangle" of ACE-I + BB + MRA 3. The addition of MRA to existing triple therapy represents completion of the foundational four-pillar regimen, not an optional enhancement.
In this patient already on three pillars of GDMT, the MRA is the missing essential component that should be added immediately to maximize survival and reduce hospitalizations.